Emerging drugs for eosinophilic esophagitis

Bibliography

• Dellon ES, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). Am J Gastroenterol 2013;108(5):679-92
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128(1):3-20; e6; quiz 21-2
   PubMed Web of Science ®Google Scholar
• Taft TH, Kern E, Keefer L, et al. Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis. J Clin Gastroenterol 2011;45(9):769-74
   PubMed Web of Science ®Google Scholar
• Hruz P, Straumann A, Bussmann C, et al. Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County. Switzerland. J Allergy Clin Immunol 2011;128(6):1349-50; e5
   PubMed Web of Science ®Google Scholar
• Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol 2011;106(8):1439-45
   PubMed Web of Science ®Google Scholar
• Fiorentino R, Liu G, Pariser AR, Mulberg AE. Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases. J Allergy Clin Immunol 2012;130(3):613-16
   PubMed Web of Science ®Google Scholar
• Straumann A, Schoepfer AM. Therapeutic concepts in adult and paediatric eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol 2012;9(12):697-704
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Chehade M. Eosinophilic esophagitis: diagnosis and management. Immunol Allergy Clin North Am 2012;32(1):67-81
   PubMed Web of Science ®Google Scholar
• Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012;142(7):1451-9; e1; quiz e14-5
   PubMed Web of Science ®Google Scholar
• Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6(2):165-73
   PubMed Web of Science ®Google Scholar
• Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131(5):1381-91
   PubMed Web of Science ®Google Scholar
• Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2012;108(3):366-72
   Web of Science ®Google Scholar
• Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10(7):742-49 e1
   PubMed Web of Science ®Google Scholar
• Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010;55(5):1313-19
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139(5):1526-37; 37 e1
   PubMed Web of Science ®Google Scholar
• Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012;143(2):321-4; e1
   PubMed Web of Science ®Google Scholar
• Gupta SK, Collins MH, Lewis JD. Efficacy and safety of oral budesonide suspension (obs) in pediatric subjects with eosinophilic esophagitis (EoE): results from the double-blind, placebo-controlled PEER Study. Gastroenterology 2011;140(Suppl 1):S179
   Google Scholar
• Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139(2):418-29
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9(5):400-9 e1.
   PubMed Web of Science ®Google Scholar
• Hirano I. Editorial: should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? Am J Gastroenterol 2013;108(3):373-5
   PubMed Web of Science ®Google Scholar
• Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012;7(11):e50037
   PubMed Web of Science ®Google Scholar
• Vashi R, Hirano I. Diet therapy for eosinophilic esophagitis: when, why and how. Curr Opin Gastroenterol 2013;29(4):407-15
   PubMed Web of Science ®Google Scholar
• Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007;73(10):1657-64
   PubMed Web of Science ®Google Scholar
• Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004;309(1):249-58
   PubMed Web of Science ®Google Scholar
• Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 2007;47(6):782-9
   PubMed Web of Science ®Google Scholar
• Vermeulen JH, Gyurkovits K, Rauer H, Engelstatter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007;101(10):2182-91
   PubMed Web of Science ®Google Scholar
• Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21(2):264-75
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 2005;314(2):568-74
   PubMed Web of Science ®Google Scholar
• Schroeder S, Fleischer DM, Masterson JC, et al. Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol 2012;129(5):1419-21
   PubMed Web of Science ®Google Scholar
• Lee JJ, Fried AJ, Hait E, et al. Topical inhaled ciclesonide for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2012;130(4):1011; author reply 11-2
   PubMed Web of Science ®Google Scholar
• Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01386112?term=Aptalis+eosinophilic+esophagitis&rank=2 [Cited 1 June 2013]
   Google Scholar
• A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01498497?term=Aptalis+eosinophilic+esophagitis&rank=1 [Cited 1 June 2013]
   Google Scholar
• OBS in Adolescent and Young Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01642212?term=Falk+pharma&rank=31 [Cited 1 June 2013]
   Google Scholar
• Dilger K, Lopez-Lazaro L, Marx C, et al. Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes. Digestion 2013;87(2):110-17
   PubMed Web of Science ®Google Scholar
• Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004;43(12):803-21
   PubMed Web of Science ®Google Scholar
• Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007;19(10):865-9
   PubMed Web of Science ®Google Scholar
• Prussin C. Sirolimus for Eosinophil-Associated Gastrointestinal Disorders. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01814059?term=eosinophilic+esophagitis+and+sirolimus&rank=1 [Cited 13 April 2013]
   Google Scholar
• Lucendo AJ. Immunopathological mechanisms of eosinophilic oesophagitis. Allergol Immunopathol (Madr) 2008;36(4):215-27
   PubMed Web of Science ®Google Scholar
• Mulder DJ, Justinich CJ. Understanding eosinophilic esophagitis: the cellular and molecular mechanisms of an emerging disease. Mucosal Immunol 2011;4(2):139-47
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sferra TJ, Eroglu Y. T Cell Co-Stimulatory Molecules: A Co-conspirator in the Pathogenesis of Eosinophilic Esophagitis? Dig Dis Sci 2013;58(6):1497-506
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129(2):456-63; 63 e1-3
   PubMed Web of Science ®Google Scholar
• Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003;125(5):1419-27
   PubMed Web of Science ®Google Scholar
• Abonia JP, Rothenberg ME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med 2012;63:421-34
   PubMed Web of Science ®Google Scholar
• Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012;61(12):1765-73
   PubMed Web of Science ®Google Scholar
• Cheng E, Souza RF, Spechler SJ. Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol 2012;303(11):G1175-87
   PubMed Web of Science ®Google Scholar
• Sherrill JD, Rothenberg ME. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. J Allergy Clin Immunol 2011;128(1):23-32; quiz 33-4
   PubMed Web of Science ®Google Scholar
• Straumann A, Hoesli S, Bussmann C, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68(3):375-85
   PubMed Web of Science ®Google Scholar
• Pettipher R, Vinall SL, Xue L, et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012;340(2):473-82
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010;59(1):21-30
   PubMed Web of Science ®Google Scholar
• Assa'ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011;141(5):1593-604
   PubMed Web of Science ®Google Scholar
• Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00635089?term=Eosinophilic+Esophagitis+and+reslizumab&rank=2 [Cited 9 April 2013]
   Google Scholar
• Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01022970?term=Eosinophilic+esophagitis+IL-13&rank=2 [Cited 9 Apr 2013]
   Google Scholar
• Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009;137(4):1238-49
   PubMed Web of Science ®Google Scholar
• Fang JC, Hilden K, Gleich GJ, et al. A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab. Gastroenterology 2011;140:5
   Google Scholar
• Alpan O. Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda, MD; 2000. Available from: http://clinicaltrials.gov/show/NCT01040598 [Cited 13 April 2013]
   Google Scholar
• Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008;122(2):425-7
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011;56(12):3551-8
   PubMed Web of Science ®Google Scholar
• Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003;52(2):181-5
   PubMed Web of Science ®Google Scholar
• Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus 2011;24(4):229-34
   PubMed Web of Science ®Google Scholar
• Filik L. Montelukast and maintenance of steroid-induced remission in eosinophilic esophagitis. Dig Dis Sci 2012;57(1):258-9
   PubMed Web of Science ®Google Scholar
• Alexander J. Trial of Montelukast in Eosinophilic Esophagitis. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00511316?term=eosinophilic+esophagitis+and+montelukast&rank=1 [Cited 13 April 2013]
   Google Scholar
• Hogan W. Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01702701?term=eosinophilic+esophagitis+and+montelukast&rank=2 [Cited 13 April 2013]
   Google Scholar
• Page S. A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01458418?term=eosinophilic+esophagitis+and+montelukast&rank=3 [Cited 13 April 2013]
   Google Scholar
• Lee RU. Allergy Immunotherapy in the Management of Eosinophilic Esophagitis (AIMEE). ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01685034?term=Eosinophilic+esophagitis+and+immunotherapy&rank=1 [Cited 13 Apr 2013]
   Google Scholar
• Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358(26):2787-95
   PubMed Web of Science ®Google Scholar
• Abonia JP. Testing Effectiveness of Losartan vs Placebo in Patients With EoE With or Without a CTD. ClinicalTrialsgov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01808196?term=eosinophilic+esophagitis+and+losartan&rank=1 [Cited 13 April 2013]
   Google Scholar
• Hirano I. Therapeutic end points in eosinophilic esophagitis: is elimination of esophageal eosinophils enough? Clin Gastroenterol Hepatol 2012;10(7):750-2
   PubMed Web of Science ®Google Scholar
• Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013;62(4):489-95
   PubMed Web of Science ®Google Scholar
• Nicodeme F, Hirano I, Chen J, et al. Esophageal Distensibility as a Measure of Disease Severity in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2013; Epub ahead of print
   Google Scholar
• Abu-Sultaneh SM, Durst P, Maynard V, Elitsur Y. Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Dig Dis Sci 2011;56(1):97-102
   PubMed Web of Science ®Google Scholar
• Lee J, Huprich J, Kujath C, et al. Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy. Clin Gastroenterol Hepatol 2012;10(5):481-6
   PubMed Web of Science ®Google Scholar
• Pentiuk S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;48(2):152-60
   PubMed Web of Science ®Google Scholar
• Aceves S, Hirano I, Furuta GT, Collins MH. Eosinophilic gastrointestinal diseases--clinically diverse and histopathologically confounding. Semin Immunopathol 2012;34(5):715-31
   PubMed Web of Science ®Google Scholar
• Caldwell JM, Blanchard C, Collins MH, et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. J Allergy Clin Immunol 2010;125(4):879-88; e8
   PubMed Web of Science ®Google Scholar
• Lu TX, Sherrill JD, Wen T, et al. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol 2012;129(4):1064-75; e9
   PubMed Web of Science ®Google Scholar
• Aceves SS, Newbury RO, Chen D, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 2010;65(1):109-16
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010;105(5):1062-70
   PubMed Web of Science ®Google Scholar